Evidence map›Paper›PMID 39572434›Full record

ReviewCurrent heart failure reports2024

Atrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment Opportunities.

Ghassan Bidaoui, Ala' Assaf, Nassir Marrouche

Abstract readReview
In one paragraph

Review in Current heart failure reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Correlation Between Dysbiosis and Atrial Fibrillation: What's New?International journal of molecular sciences · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ghassan BidaouiTulane Research Innovation for Arrhythmia Discovery (TRIAD), New Orleans, LA, USA.
Ala' AssafTulane Research Innovation for Arrhythmia Discovery (TRIAD), New Orleans, LA, USA.
Nassir MarroucheTulane Research Innovation for Arrhythmia Discovery (TRIAD), New Orleans, LA, USA. nmarrouche@tulane.edu.ORCID http://orcid.org/0000-0003-0970-9182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewAtrial fibrillation and heart failure frequently co-exist. This review discusses the comorbidity of atrial fibrillation and heart failure, the bi-directional link between them, and the recent advances in the management of these co-existing diseases. RECENT

findingsCatheter ablation received a class 1 A recommendation for patients with AF and HF, after overwhelming evidence in heart failure with reduced ejection fraction and end-stage heart failure, while clinical trials are still lacking in patients with preserved ejection. Guideline-medical therapy of heart failure decreases the incidence of atrial fibrillation and the progression of atrial myopathy. Based on the current evidence, management of patients with both HF and AF should be include early optimization of comorbidity control, guideline-medical therapy for heart failure, and rhythm control preferentially through catheter ablation in properly selected patients.

Indexed as

Atrial FibrillationCatheter AblationHeart FailureAnti-Arrhythmia AgentsComorbidityHumansStroke VolumeAnti-Arrhythmia AgentsArtificial intelligenceAtrial fibrillationAtrial myopathyCatheter ablationHeart failure

Identifiers

PMID39572434
PMCPMC11582326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.